PharmaceuticalsSilver report

Published April 2026Insight Research10 min read2026 Edition20 sources, 20 primary-gradeVery high source depth

Thailand Pharma Generic vs Branded Deep Dive

Thai pharma ~THB 250B. Generic ~60% vol / ~30% value; branded ~40% vol / ~65% value; biosimilar emerging. SPC, Mega, GPO, Siam Bioscience vs Pfizer, Novartis, Roche MNC.

Key takeaways

1
Thai pharma ~. Generic ~ by volume / ~ by value; branded innovator ~ / ~; biosimilar, biotech ~ value emerging.
2
Thai generic manufacturers: Siam Pharmaceutical (SET: SPC), Thai Nakorn Patana, Mega Lifesciences (SET: MEGA), Pharmahof. GPO (Government Pharmaceutical Organization) state manufacturer produces NLEM generics, sole Thai medical-cannabis extract producer.
3
Biosimilar, biotech: Siam Bioscience (HM King-owned) produced AstraZeneca COVID-19 vaccine 2021-23; insulin, HGH, mAb biosimilars in pipeline.
4
Branded innovator MNCs: Pfizer, Novartis, Roche, GSK, Abbott, Sanofi, MSD, Bayer, Eli Lilly, J&J dominate premium brands. Patent cliff 2025-27 opens biosimilar entry on several high-value biologics.
5
Regulation: FDA, DMS, Drug Act, Patent Act. 2006-07 compulsory license precedents (ARV, CVD). CSMBS, NHSO UCS, SSO, NLEM drive generic substitution; PReMA, TPMA industry bodies.

Executive summary

Thai pharma ~ 2024. Generic accounts for ~ by volume but ~ by value — typical EM structure with price-sensitive public formulary. Branded innovator ~ volume / ~ value via premium patent-protected originator brands. Biosimilar, biotech emerging at ~ value with GPO, Siam Bioscience production, growing NLEM inclusion.^{[, , , ]}

Thai generic: Siam Pharmaceutical (SET: SPC) listed-equity leader; Thai Nakorn Patana mid-size generic, OTC; Mega Lifesciences (SET: MEGA) Thai, ASEAN, nutraceutical; Pharmahof hospital generic. GPO state manufacturer produces NLEM, medical-cannabis extract. Siam Bioscience (HM King-owned) runs biotech, biosimilar — produced AstraZeneca COVID-19 vaccine under 2021-23 agreement; insulin, HGH, monoclonal antibody biosimilars in pipeline targeting patent-cliff originator drugs 2025-27.^{[, , , , , ]}

Branded innovator dominated by MNCs. Patent cliff 2025-27 for oncology, CVD, CNS biologics opens ~ Thai biosimilar opportunity. Regulation: FDA, DMS, Drug Act, Patent Act; 2006-07 compulsory license precedents (efavirenz, lopinavir/ritonavir, clopidogrel, imatinib, letrozole, docetaxel). CSMBS (~), NHSO UCS (~), SSO (~), NLEM, hospital formulary drive generic substitution. PReMA, IFPMA Thailand affiliate represent innovator; TPMA represent local generic.^{[, , , , , , , , , , ]}

GPO, FDA, DMS, NHSO, NLEM, TPMA, PReMA, SPC, TNP, MEGA, Pharmahof, Siam Bioscience, innovator, SCB EIC, Krungsri

Data as of: FY2024

Thai pharma value mix (% of FY2024 sales)

Branded innovator

Share %

65%

Players

Pfizer, Novartis, Roche, GSK, Abbott, Sanofi, MSD

Generic

Share %

30%

Players

SPC, TNP, MEGA, Pharmahof, GPO, regional

Biosimilar, biotech

Share %

Players

GPO, Siam Bioscience, regional biosimilar

Type	Share %	Players
Branded innovator	65%	Pfizer, Novartis, Roche, GSK, Abbott, Sanofi, MSD
Generic	30%	SPC, TNP, MEGA, Pharmahof, GPO, regional
Biosimilar, biotech	5%	GPO, Siam Bioscience, regional biosimilar

TPMA, PReMA, NHSO, hospital formulary triangulation

Data as of: FY2024

Analyst framing

Why this report

Thai pharma is branded-value-dominant, generic-volume-heavy, biosimilar-emerging. Patent cliff 2025-27, NLEM expansion, Siam Bioscience capability drive substitution.

Manufacturer, patent, biosimilar playbooks

Thai generic: SPC, TNP, MEGA, Pharmahof, GPO core manufacturers. Regional Indian, Korean generics also compete via Thai FDA-registered imports. GPO state manufacturer used Compulsory License leverage in 2006-07 ARV, CVD procurement.

Siam Bioscience (HM King-owned) biotech, biosimilar: AstraZeneca COVID-19 vaccine 2021-23 agreement; pipeline: insulin, HGH, monoclonal antibody biosimilars targeting patent-cliff originators 2025-27. Patent cliff ~THB 5-10B biosimilar opportunity.

Branded innovator: Pfizer, Novartis, Roche, GSK, Abbott, Sanofi, MSD Thailand dominate. Patent-protected originator, CSMBS/NHSO/SSO premium pricing, hospital-formulary driving volume; post-patent genericisation then price erosion. 2006-07 compulsory license events shape MNC-government relations. CSMBS, NHSO UCS, SSO, NLEM drive generic substitution. PReMA, IFPMA Thailand affiliate, TPMA represent innovator vs local generic.

Scenarios to 2031

Bull: biosimilar, patent cliff, NLEM

Biosimilar ~15% value

Siam Bioscience, GPO, regional biosimilar capture patent-cliff biologics; NLEM expands; CSMBS, NHSO procurement accelerates substitution.

Base case

Biosimilar ~8-10% value

Steady biosimilar adoption; patent cliff materialises selectively; NLEM incremental; generic stable.

Bear: patent extension, pricing

Biosimilar <5% value

Patent extensions, data exclusivity delay biosimilar; NLEM delays; MNC, government reach price-volume deals.

Unlock the full report

Manufacturer playbooks, patent cliff, biosimilar opportunity, NLEM dynamics, scenarios.

Unlock deep dive·$149-$199

Need more than the web report? Ask for a scoped export or source appendix.

Every report keeps visible citations and source metadata. Terms.

Related reports

Thailand Pharmaceuticals Market Intelligence

Thailand's pharmaceuticals market reached approximately THB 280B in FY2024, split roughly 75% imported (originators, generics) and 25% domestic (GPO state, listed, private generics). Government Pharmaceutical Organisation is the state anchor for essential medicines, ARV, biosimilar manufacturing. Mega Lifesciences (SET: MEGA) is the largest Thai-listed pharma (~THB 16B revenue). Multinational originator subsidiaries (GSK, Pfizer, Novartis, Roche) lead originator, specialty supply. UCS, SSS, CSMBS multi-payer framework, NLEM reimbursement drive price-competition dynamics.

Open report →

Thailand Life Sciences, Biotech, GPO BioPharm Deep Dive

Thai life-sci, biotech anchored by GPO (state generics, vaccine), Siam Bioscience (Crown Property biopharma — AstraZeneca COVID partner), Bumrungrad/BDMS clinical-trial sites, Mahidol/Chula research. EEC Genomics Thailand, biopharma investment incentive, ASEAN CRO hub positioning.

Open report →

Thailand Diabetes, Insulin, Chronic Disease Pharma Deep Dive

Deep-dive into Thai diabetes, chronic-disease pharma market ~THB 30-40B FY2024. Diabetic population ~5-6M (~10-11% adults), ~1.5-2M on insulin. Insulin: Novo Nordisk, Sanofi, Eli Lilly dominate originator, biosimilar. GLP-1 (semaglutide Ozempic, Wegovy, tirzepatide Mounjaro) recent, premium-priced, supply-constrained. Other chronic: hypertension, dyslipidaemia, statin, cardiovascular, kidney, osteoporosis, neuropathy, retinopathy. UC, Social Security, CSMBS schemes cover NLEM essential medicines; private, retail pharmacy, insurance covers premium GLP-1. Local generic: GPO, Siam Pharmaceutical, LBS, Thai Otsuka. Thai FDA, MoPH, Thai Diabetes Association.

Open report →

The Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway, and Generic Substitution

Thailand's pharmaceuticals market reaches estimated THB 220-280B annual with ~60% imported branded-pharma (multinational) plus ~40% Thai-domestic-generic (originator, generic-substitute). Major multinational brands operating Thai market via Thai-licensed entity or Thai-licensee distribution: Pfizer Thailand, Sanofi Thailand, Novartis Thailand, Roche Thailand, Bayer Thailand, Boehringer Ingelheim Thailand, AstraZeneca Thailand, Merck (US-MSD) Thailand, Johnson & Johnson Thailand, GSK Thailand, Eli Lilly Thailand, Bristol-Myers Squibb Thailand. Thai-domestic-generic operators: GPO (Government Pharmaceutical Organization, state-owned, structural Thai-domestic anchor), Siam Bioscience (Crown-Property Bureau-owned, COVID-19 vaccine, biologics), Berlin Pharmaceutical Industry, Thai Otsuka, Olic, Siam Pharmaceutical, Greater Pharma. Distribution channels: hospital-procurement (BDMS, Bumrungrad, Phyathai-affiliated, government hospitals), retail-pharmacy (Pure Pharmacy, Watson, Boots, Save Drug, Fascino), wholesale (DKSH Thailand structural foreign-multinational distribution leader, Zuellig Pharma Thailand). Thai FDA Drug Act B.E. 2510 (1967, revised) approval pathway: New Drug Application, product registration, GMP compliance. NLEM (National List of Essential Medicines) drives public-procurement substitution to generic-equivalent. CL (Compulsory Licensing) precedent 2007-2008 for HIV ARVs (efavirenz) drove generic-substitution win for Thai government during Ministry-of-Public-Health-led campaign. Watch CL-precedent revival risk and biosimilar-approval framework evolution.

Open report →